The cancer risk according to three subtypes of ANCA-associated vasculitis: A propensity score-matched analysis of a nationwide study

Jennette, 2013, Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis, Annu Rev Pathol, 8, 139, 10.1146/annurev-pathol-011811-132453 Watts, 2007, Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies, Ann Rheum Dis, 66, 222, 10.1136/ard.2006.054593 Falk, 2011, Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis, Ann Rheum Dis, 70, 704, 10.1136/ard.2011.150714 Masi, 1990, The American college of rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis), Arthritis Rheum, 33, 1094, 10.1002/art.1780330806 Cornec, 2016, ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients, Nat Rev Rheumatol, 12, 570, 10.1038/nrrheum.2016.123 Berden, 2012, Diagnosis and management of ANCA associated vasculitis, BMJ, 344, e26, 10.1136/bmj.e26 Faurschou, 2015, Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis, Rheumatology, 54, 1345, 10.1093/rheumatology/keu372 Knight, 2004, Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide, Ann Rheum Dis, 63, 1307, 10.1136/ard.2003.019125 Baker, 1987, Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study, Am J Med, 83, 1, 10.1016/0002-9343(87)90490-6 Radis, 1995, Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study, Arthritis Rheum, 38, 1120, 10.1002/art.1780380815 Heijl, 2011, Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European vasculitis study group clinical trials, Ann Rheum Dis, 70, 1415, 10.1136/ard.2010.145250 Knight, 2002, Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis, Int J Cancer, 100, 82, 10.1002/ijc.10444 Pankhurst, 2004, Malignancy is increased in ANCA-associated vasculitis, Rheumatology, 43, 1532, 10.1093/rheumatology/keh374 Rahmattulla, 2015, Incidence of malignancies in patients with antineutrophil cytoplasmic antibody-associated vasculitis diagnosed between 1991 and 2013, Arthritis Rheumatol, 67, 3270, 10.1002/art.39317 van Daalen, 2017, Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis, Ann Rheum Dis, 76, 1064, 10.1136/annrheumdis-2016-209925 Zycinska, 2013, Cancer incidence in pulmonary vasculitis, Adv Exp Med Biol, 788, 349, 10.1007/978-94-007-6627-3_47 Heijl, 2020, Malignancies in patients with antineutrophil cytoplasmic antibody-associated vasculitis: a population-based cohort study, J Rheumatol, 47, 1229, 10.3899/jrheum.181438 Yoo, 2018, Cancer development in Korean patients with ANCA-associated vasculitis: a single centre study, Clin Exp Rheumatol, 36, 73 Leavitt, 1990, The American college of rheumatology 1990 criteria for the classification of Wegener's granulomatosis, Arthritis Rheum, 33, 1101, 10.1002/art.1780330807 Jennette, 2013, 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides, Arthritis Rheum, 65, 1, 10.1002/art.37715 Austin, 2010, Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score, Am J Epidemiol, 172, 1092, 10.1093/aje/kwq224 Shang, 2015, Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies, PLoS One, 10, 10.1371/journal.pone.0126016 Sriskandarajah, 2017, Cancer in ANCA-associated glomerulonephritis: a registry-based cohort study, Int J Nephrol, 2017, 10.1155/2017/6013038 Faurschou, 2008, Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients, J Rheumatol, 35, 100 Folci, 2019, ANCA-associated vasculitides and hematologic malignancies: lessons from the past and future perspectives, J Immunol Res, 2019, 10.1155/2019/1732175 Matz, 2017, Review of advances in uroprotective agents for cyclophosphamide- and ifosfamide-induced hemorrhagic cystitis, Urology, 100, 16, 10.1016/j.urology.2016.07.030 Harahap, 2020, Quantification of 3-hydroxypropyl mercapturic acid in the urine of patients with breast cancer to monitor cyclophosphamide toxicity, Ther Drug Monit, 10.1097/FTD.0000000000000737 Lee, 2015, Cigarette side-stream smoke lung and bladder carcinogenesis: inducing mutagenic acrolein-DNA adducts, inhibiting DNA repair and enhancing anchorage-independent-growth cell transformation, Oncotarget, 6, 33226, 10.18632/oncotarget.5429 Wester Trejo, 2018, Antineutrophil cytoplasmic antibody-associated vasculitis and malignancy, Curr Opin Rheumatol, 30, 44, 10.1097/BOR.0000000000000448 Tatsis, 1999, Wegener's granulomatosis associated with renal cell carcinoma, Arthritis Rheum, 42, 751, 10.1002/1529-0131(199904)42:4<751::AID-ANR19>3.0.CO;2-D Faurschou, 2009, Cancer preceding Wegener's granulomatosis: a case-control study, Rheumatology, 48, 421, 10.1093/rheumatology/kep009 Yates, 2016, EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis, Ann Rheum Dis, 75, 1583, 10.1136/annrheumdis-2016-209133 Berti, 2017, The epidemiology of antineutrophil cytoplasmic autoantibody-associated vasculitis in olmsted county, minnesota: a twenty-year US population-based study, Arthritis Rheumatol, 69, 2338, 10.1002/art.40313 Herlyn, 2014, Doubled prevalence rates of ANCA-associated vasculitides and giant cell arteritis between 1994 and 2006 in northern Germany, Rheumatology, 53, 882, 10.1093/rheumatology/ket440 Greco, 2015, Churg-strauss syndrome, Autoimmun Rev, 14, 341, 10.1016/j.autrev.2014.12.004 Kim, 2017, Towards actualizing the value potential of Korea health insurance review and assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data, J Korean Med Sci, 32, 718, 10.3346/jkms.2017.32.5.718 Westman, 1998, Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement, J Am Soc Nephrol, 9, 842, 10.1681/ASN.V95842 Holle, 2011, Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades, Arthritis Rheum, 63, 257, 10.1002/art.27763